The thing that stopped me cold this week was not the science. It was the disclosure section.

A group of obesity specialists published a commentary in Gastroenterology with a headline that traveled fast: Ozempic changed everything, but the real revolution is next. The piece, “Revisiting POWER in the GLP-1 Age,” updates a 2017 obesity-care framework and argues that GLP-1 drugs are only one piece of the puzzle. The future, the authors say, is a multidisciplinary stack: drugs plus endoscopic procedures plus bariatric surgery plus precision medicine that genetically matches you to the right intervention.

It is a genuinely interesting clinical idea, and I’ll get to why I think parts of it are right. But first, follow the money, because nobody in the press coverage did.

Who profits from “what comes next”

The lead author, Andres Acosta of the Mayo Clinic, runs a precision-obesity lab and co-founded Phenomix Sciences, a company that sells exactly the thing the commentary calls the future: a test that sorts you into obesity “phenotypes” (Hungry Gut, Hungry Brain, and the rest) to pick your treatment. In his own peer-reviewed disclosure statements, Acosta lists stock in Phenomix and Gila Therapeutics plus consulting arrangements with drugmakers, and the patent on the phenotyping method is licensed to his company.

So when a commentary tells you the next era of obesity care is precision-medicine phenotyping and gastroenterologist-delivered endoscopic procedures, notice who wrote it: a phenotyping-company founder, published in Gastroenterology, the American Gastroenterological Association’s own journal, the home venue of the specialists who perform and bill for those endoscopic procedures. None of that makes the science wrong. It makes the framing a sales pitch in a lab coat, and the press releases that amplified it left the disclosures on the cutting-room floor.

The “revolution” pill that works less well than the shot

Now the part that genuinely surprised me, because it cuts against the hype from the other direction.

The drug everyone is calling the next leap is orforglipron, Eli Lilly’s oral GLP-1, which the FDA approved on April 1 for weight management and Lilly now sells as Foundayo. A pill instead of a needle is a real convenience win, and unlike the existing oral Wegovy, you can take it any time without the empty-stomach ritual. I wanted to be impressed.

Then I read the numbers. In the pivotal ATTAIN-1 trial of 3,127 adults, orforglipron at its highest dose produced about 11 percent weight loss over 72 weeks. Sounds good, until you set it beside its injectable cousins. The oral semaglutide pill manages around 13.6 percent. And tirzepatide, the Zepbound shot, hit 22.5 percent at its top dose over the same window. The “breakthrough” oral drug is, on the metric patients are actually being sold, the weakest of the three. It is easier to swallow, and that is most of the story.

Weight loss by GLP-1 drug (% body weight)
Orforglipron (pill)11%Oral semaglutide13.6%Tirzepatide (shot)22.5%
The 'breakthrough' oral pill trails both its oral and injectable competitors on the metric patients are being sold. Source: ATTAIN-1 (NEJM, 2026); oral semaglutide review (PMC, 2026); SURMOUNT-1 (Eli Lilly)

Easier is not nothing. A pill Lilly can manufacture at scale could keep pushing cash prices down toward a few hundred dollars a month, well under the four-figure list tags injectables launched with, and that matters enormously for anyone paying out of pocket. But “convenient and a bit less effective” is a very different sentence than “revolution,” and only one of them moves product.

The hole in the middle of the story

Here is the question the curious-reader part of my brain kept circling: if these drugs are so transformative, what happens when you stop?

We have an answer, and the revolution talk walks right past it. In the STEP 1 extension, people who had lost an average of 17 percent of their body weight on semaglutide regained two-thirds of it within a year of stopping, and their blood pressure and cholesterol drifted back up alongside the pounds. These are not weight-loss drugs the way a course of antibiotics is an infection drug. They are maintenance drugs, and you are either on them or the biology reasserts itself.

There is a quieter problem in what you lose. Across GLP-1 trials, an estimated 40 to 60 percent of the weight shed is lean mass, the body tissue that includes muscle, not only fat. The worry, and it is a legitimate one, is that the weight you regain after quitting skews back toward fat. Shed lean tissue on the way down, put fat back on the way up, and you could finish a “course of treatment” with a worse body composition than you started with. That is exactly the kind of concern a commentary celebrating the next shiny intervention has no incentive to sit with.

Where the experts are actually right

I came in ready to write off the whole “multidisciplinary future” pitch as turf-building, and the evidence honestly pulled me partway back, so let me be specific about where.

The body defends its fat stores through more than one pathway, which is why yanking a single lever and expecting the result to hold has never worked. The POWER commentary’s strongest claim is that pairing a drug with structured nutrition and, critically, resistance training protects the lean mass those drugs strip, and the muscle-loss data above is precisely why that pairing is not optional. Add surgery for the patients who need it, and you are treating obesity like the redundant, defended system it is instead of throwing one molecule at it and walking away. The clinical instinct is sound.

My objection is narrower, and it is about who gets to narrate it. When the people announcing the next revolution are the ones holding the patents, the stock, and the procedure codes for that revolution, you are owed the disclosures right next to the headline. The science deserves a hearing. So does the question of who gets paid when you believe it.

What would I actually watch? Whether orforglipron’s price drop reaches people without good insurance. Whether anyone funds the long, boring trials on what a decade of these drugs does to muscle. And whether “precision phenotyping” ever proves it beats a doctor who simply pays attention. Until then, I’ll take the pill news for what the data shows, a convenient and somewhat weaker option, and treat the word “revolution” as what it usually is in medicine: a marketing budget.

Sources

  1. Gastroenterology – “Revisiting POWER in the GLP-1 Age,” POWER commentary (Acosta et al., 2026)
  2. ScienceDaily – “Ozempic changed obesity treatment, but experts say the real revolution is next” (2026)
  3. News-Medical – Experts outline a multidisciplinary approach to managing clinical obesity (2026)
  4. Fierce Healthcare – Health2047/AMA spins out obesity-testing startup Phenomix Sciences
  5. Obesity (Wiley) – Acosta et al., phenotype-based weight-loss trial with author financial disclosures (2021)
  6. NEJM – Orforglipron for obesity, ATTAIN-1 phase 3 results (2026)
  7. Eli Lilly – FDA approves Foundayo (orforglipron), oral GLP-1 for weight loss (April 2026)
  8. PMC – “From needles to pills: oral GLP-1 therapy enters the obesity arena,” oral semaglutide comparison review (2026)
  9. Eli Lilly – SURMOUNT-1 results in NEJM, tirzepatide up to 22.5% weight loss
  10. NBC News – Falling prices of Wegovy, Zepbound and oral GLP-1s
  11. PubMed – Weight regain after withdrawal of semaglutide, STEP 1 trial extension (2022)
  12. eClinicalMedicine (The Lancet) – Trajectory of weight regain after GLP-1 cessation, with lean-mass findings (2026)